Expression profiles of 507 proteins from a biotin label-based antibody array in human colorectal cancer

Miyoshi,Hisaaki; Morishita,Asahiro; Tani,Joji; Sakamoto,Teppei; Fujita,Koji; Katsura,Akiko; Tatsuta,Miwa; Nomura,Takako; Yoneyama,Hirohito; Iwama,Hisakazu; Suzuki,Yasuyuki; Masaki,Tsutomu

doi:10.3892/or.2013.2935

Expression profiles of 507 proteins from a biotin label-based antibody array in human colorectal cancer

Authors:
- Hisaaki Miyoshi
- Asahiro Morishita
- Joji Tani
- Teppei Sakamoto
- Koji Fujita
- Akiko Katsura
- Miwa Tatsuta
- Takako Nomura
- Hirohito Yoneyama
- Hisakazu Iwama
- Yasuyuki Suzuki
- Tsutomu Masaki
View Affiliations

Affiliations: Department of Gastroenterology and Neurology, Kagawa University Faculty of Medicine, Kita-gun, Kagawa 761-0793, Japan, Life Science Research Center, Kagawa University Faculty of Medicine, Kita-gun, Kagawa 761-0793, Japan, Department of Gastroenterological Surgery, Kagawa University Faculty of Medicine, Kita-gun, Kagawa 761-0793, Japan
Published online on: December 19, 2013 https://doi.org/10.3892/or.2013.2935
Pages: 1277-1281

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Molecular-targeted therapy is one of the most promising therapies for patients with advanced-stage colorectal cancer (CRC). However, a wide range of proteins have unknown expression levels in CRC. The purpose of the present study was to determine the expression levels of various proteins related to colorectal carcinogenesis and cancer development. We examined the expression levels of 507 target proteins using a biotin label-based antibody array in 6 human CRC tissues. We also analyzed the clinicopathological features of CRC patients. In CRC tissues, IL-1α, GRO, Glut5, MIG, ICAM-5, VE-cadherin, uPA and Leptin R were increased when compared to levels in normal colon tissues. MPIF-1/CCL23, FGF R5, MIP2, SAA and IL-18 Rβ were strongly upregulated in rectal cancer when compared to the levels in non-rectal cancer. These data suggest that differential protein expression profiles exist under different conditions, including carcinogenesis and CRC localization. Therefore, an exhaustive analysis of protein expression levels using a biotin label-based antibody protein array is a potentially useful tool for identifying novel individual therapies for CRC patients.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
2	Paik SS, Jang SM, Jang KS, Lee KH, Choi D and Jang SJ: Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann Surg Oncol. 16:297–303. 2009. View Article : Google Scholar
3	Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 24:1625–1638. 2003. View Article : Google Scholar : PubMed/NCBI
4	Devine RM and Dozois RR: Surgical management of locally advanced adenocarcinoma of the rectum. World J Surg. 16:486–489. 1992. View Article : Google Scholar : PubMed/NCBI
5	Wang Y, Cummings B, Catton P, et al: Primary radical external beam radiotherapy of rectal adenocarcinoma: long term outcome of 271 patients. Radiother Oncol. 77:126–132. 2005. View Article : Google Scholar : PubMed/NCBI
6	Prados J, Melguizo C, Ortiz R, et al: Colon cancer therapy: recent developments in nanomedicine to improve the efficacy of conventional chemotherapeutic drugs. Anticancer Agents Med Chem. Mar 4–2013.(Epub ahead of print).
7	Huang RP, Yang W, Yang D, Flowers L, Horowitz IR, Cao X and Huang R: The promise of cytokine antibody arrays in the drug discovery process. Expert Opin Ther Targets. 9:601–615. 2005. View Article : Google Scholar : PubMed/NCBI
8	Morishita A, Gong J, Nomura T, et al: The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer. Int J Oncol. 37:829–835. 2010. View Article : Google Scholar : PubMed/NCBI
9	Auyeung KK, Law PC and Ko JK: Novel anti-angiogenic effects of formononetin in human colon cancer cells and tumor xenograft. Oncol Rep. 28:2188–2194. 2012.PubMed/NCBI
10	Yoshida S, Masaki T, Feng H, et al: Enhanced expression of adaptor molecule p46 Shc in nuclei of hepatocellular carcinoma cells: study of LEC rats. Int J Oncol. 25:1089–1096. 2004.PubMed/NCBI
11	Yukimasa S, Masaki T, Yoshida S, et al: Enhanced expression of p46 Shc in the nucleus and p52 Shc in the cytoplasm of human gastric cancer. Int J Oncol. 26:905–911. 2005.PubMed/NCBI
12	Boozer C, Kim G, Cong S, Guan H and Londergan T: Looking towards label-free biomolecular interaction analysis in a high-throughput format: a review of new surface plasmon resonance technologies. Curr Opin Biotechnol. 17:400–405. 2006. View Article : Google Scholar : PubMed/NCBI
13	Huang R, Jiang W, Yang J, et al: A biotin label-based antibody array for high-content profiling of protein expression. Cancer Genomics Proteomics. 7:129–141. 2010.PubMed/NCBI
14	Matsuo Y, Sawai H, Ma J, et al: IL-1α secreted by colon cancer cells enhances angiogenesis: the relationship between IL-1α release and tumor cells’ potential for liver metastasis. J Surg Oncol. 99:361–367. 2009.
15	Haber RS, Rathan A, Weiser KR, et al: GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 83:34–40. 1998. View Article : Google Scholar : PubMed/NCBI
16	Langenskiold M, Holmdahl L, Angenete E, Falk P, Nordgren S and Ivarsson ML: Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer. Tumour Biol. 30:210–220. 2009. View Article : Google Scholar : PubMed/NCBI
17	Ruehlmann JM, Xiang R, Niethammer AG, et al: MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res. 61:8498–8503. 2001.PubMed/NCBI
18	Wen Y, Giardina SF, Hamming D, et al: GROα is highly expressed in adenocarcinoma of the colon and down-regulates fibulin-1. Clin Cancer Res. 12:5951–5959. 2006.
19	Maruya SI, Myers JN, Weber RS, Rosenthal DI, Lotan R and El-Naggar AK: ICAM-5 (telencephalin) gene expression in head and neck squamous carcinoma tumorigenesis and perineural invasion! Oral Oncol. 41:580–588. 2005.PubMed/NCBI
20	Sulkowska M, Famulski W, Wincewicz A, et al: Levels of VE-cadherin increase independently of VEGF in preoperative sera of patients with colorectal cancer. Tumori. 92:67–71. 2006.PubMed/NCBI
21	Uddin S, Bavi PP, Hussain AR, et al: Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. Carcinogenesis. 30:1832–1840. 2009. View Article : Google Scholar : PubMed/NCBI
22	Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI